Skip to main content

Stoke Therapeutics

Stoke Therapeutics Inc is an American clinical-stage biotechnology company developing RNA-targeted antisense oligonucleotide medicines to treat severe genetic diseases. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output platform to restore protein levels by upregulating gene expression, with lead candidate zorevunersen targeting Dravet syndrome. Main revenue drivers currently comprise investment capital, research grants, and potential biopharmaceutical milestone payments as clinical pipeline development advances. Stoke Therapeutics targets pediatric neurologists, clinical trial networks, specialized research centers, and patients suffering from rare genetic neurodegenerative conditions across North America and Europe. The company holds an innovative position in precision RNA therapeutics and genetic upregulation medicine. Headquartered in Bedford, Massachusetts, Stoke Therapeutics Inc is listed on the Nasdaq Stock Market.

4 of the funds FundTelligence covers report a position in Stoke Therapeutics.

Legal name
STOKE THERAPEUTICS
Sector
Health Care
Country
United States
Funds holding it
4
Exposure themes
Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics

Funds holding Stoke Therapeutics

Loading...